Thank you for standing by. My name is Gale, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ardent Health Partners second quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press Star one again. I would now like to turn the conference over to Stefan Neely, Vallum Advisors. You may begin. Thank you, operator, and welcome to Ardent Health's second quarter 2024 results conference call. Leading the call with me today is Ardent's President and CEO, Marty Bonick, and Alfred Lumsdaine, Chief Financial Officer. Today's discussion contains forward-looking statements about future business and financial expectations. Factual results may differ significantly from those projected in today's forward-looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the SEC. Except as required by law, we undertake no obligation to update our forward-looking statements. Further, this call will include the discussion of certain non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDAR. Reconciliation of these measures to the closest GAAP financial measure is included in our quarterly earnings press release, which was issued yesterday evening after the market closed and is available at ardenthealth.com. At the conclusion of our prepared remarks, we will open the line for questions. With that, I would like to turn the call over to Marty. Thank you, Stefan, and good morning, everyone. We appreciate you all joining us today for our first earnings call as a public company and for your support as we begin this exciting new chapter. I want to particularly acknowledge our team, including the more than 24,000 team members, each of whom work hard every day to deliver on our purpose of caring for our patients, our communities, and one another. Today, I'll provide a brief summary of our second quarter financial results, share some key strategic updates, and discuss our outlook for the rest of 2024. But first, I would like to take a moment to give a brief overview of Ardent and our compelling growth story. Ardent is a leading hospital operator and healthcare provider in eight growing mid-sized urban markets across six states, including Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. We deliver care through a system of 30 hospitals and more than 200 sites of care. At our core, Ardent is committed to making healthcare better. We strive to achieve this goal through an operating philosophy that puts the patient, our consumer, at the center of everything that we do. By creating this consumer focus, we cultivate deep and long-lasting relationships with our patients that span their entire healthcare journey. To aid in this, we leverage technology within our facilities and beyond to expand our relationships with patients, making care easier to access, easier to deliver, and easier to experience. We believe our differentiated care delivery model creates a unique and scalable growth platform. Our strategic framework is centered around market share growth, operational excellence, and disciplined capital deployment. Through this strategic framework, we believe that we are well-positioned to create sustainable long-term growth and value for our shareholders and for the markets that we serve. Key to our growth strategy is a differentiated joint venture model, which enables us to build local market density in new markets while also being capital efficient. Now, looking at the second quarter, our results were supported by broad-based demand growth for our services, improved payer mix and reimbursement dynamics, along with continued strategic execution. The strong demand we experienced for our services during the second quarter resulted in a 3.4% increase in adjusted admissions relative to last year. Demand trends remained favorable across both inpatient and outpatient settings, as total admissions grew 5.1% year-over-year. Inpatient volume growth was supported by an increase in admissions through the emergency department, partially due to strong growth in our EMS ED volumes. Another important dynamic impacting our inpatient volumes during the second quarter was the Two- Midnight Rule, which we estimated drove more than a 2% increase in admissions compared to the second quarter of last year. Surgery volumes decreased 2.2% compared to the prior year period. The decrease in surgeries was due to a 0.9% decrease in our inpatient surgeries and a 2.8% decrease in outpatient surgeries. Outpatient surgeries were particularly impacted by our service line optimization efforts, which reduced volumes in select lower-margin services such as dental, otolaryngology, and ophthalmology. Our inpatient surgical volume trends for the quarter reflect a decrease in bariatric and gynecological cases, partially offset by growth in higher acuity spine, neurology, and urology cases. Turning now to an update on our growth strategy. Our team is focused on advancing our key initiatives of targeted market share growth, operational excellence, and disciplined capital allocation. When combined, we believe our strategy can allow us to achieve sustainable long-term organic revenue growth in the mid to high single digits, Adjusted EBITDA growth in the low to mid double digits, and Adjusted EBITDAR margins. Our plan to grow our market share is centered around improving access to healthcare within our markets. To achieve this, we are focused on investing in additional ambulatory sites of care, such as urgent care centers, freestanding emergency rooms, outpatient surgery centers, and physician clinics. We are also deepening our network of employed providers to widen the top of the funnel in terms of patient access. Through the first half of this year, we have acquired or opened eight urgent care clinics and are actively evaluating numerous ambulatory investment opportunities within our existing markets. Urgent care facilities are currently our most immediate focus as they broaden our geographic footprint and access to new patients in our communities. As it relates to our provider network, we employed 1,785 providers at the end of the second quarter, an increase of 6.5% compared to the same time last year.... We are currently focused on recruiting both primary care and specialty care providers to expand access in our markets to support our targeted service line growth strategies. In terms of operational excellence, as I've already mentioned, we've been very focused on service line optimization, which was an initiative we began in the second half of last year. Year-to-date our service line optimization efforts have focused on curtailing low margin and low acuity cases, causing a nearly 2% decrease in our total surgery volumes and resulting in improved margins overall. We are also making strong progress improving our supply utilization through a variety of sourcing and procurement initiatives, along with other enterprise standardization initiatives. These efforts, combined with our service line optimization initiatives, contributed to the 70 basis point improvement in Adjusted EBITDAR margins relative to the second quarter of 2023. In addition, fundamental to our growth strategy is a focus on disciplined capital allocation, which includes maintaining a lean balance sheet to support opportunistic growth through investment in M&A. With the completion of our initial public offering last month, we have substantial available liquidity to pursue expansion into new and adjacent high-growth, mid-size urban markets. Our current pipeline of potential opportunities is robust, and we are actively evaluating potential targets that represent attractive return opportunities for growth. As we look forward to the second half of the year, we continue to expect strong demand for growth across our markets, along with continued margin expansion and strategic execution. To that end, yesterday, we initiated guidance for the full-year of 2024. Alfred will provide more on our guidance in a moment, but I do want to highlight a few key elements of our guidance, which includes total revenue growth of between 6% and 9% and Adjusted EBITDA growth of between 32% and 38%. In closing, I'm very proud of the hard work and commitment of our entire team, which has allowed us to reach this important milestone for Ardent. As we enter into this new chapter in growth, in partnership with all of our shareholders, we are excited about the growth opportunities ahead and believe we have an exciting roadmap to create value for shareholders while continuing to improve access to healthcare in the markets we serve. With that, I'll now hand the call over to Alfred. Thank you, Marty, and good morning to everyone joining us on the call today. As Marty indicated, we're pleased with our second quarter results, which reflected both improved revenue realization and margin expansion. Our total revenue for the quarter was $1.5 billion, an increase of 7.5% compared to the second quarter of 2023. As Marty noted, the growth in our total revenue was the result of increased volumes and better rates, partially due to improved payer and service mix. Our net patient service revenue mix for the second quarter reflects a 70 basis point reduction in Medicaid revenue mix, offset by a 55 basis point increase in managed care and a 55 basis increase in Medicare, which includes managed Medicare. Our net patient service revenue mix for the second quarter reflects a 70 basis point reduction in Medicaid revenue mix, offset by a 55 basis point increase in managed care and a 55 basis point increase in Medicare, which includes managed Medicare. Of note, these changes in payer mix reflect the ongoing Medicaid redeterminations. So far, we've seen approximately 2/3 of our redetermined patients stay within government coverage and approximately 20% convert to commercial plans. In addition, our total revenue for the second quarter reflects a $13 million increase in our supplemental revenues due to the implementation of the Oklahoma DPP program, which became effective on April first of this year. Adjusted EBITDA for the quarter was $122 million, compared to $102 million in the second quarter of 2023. Adjusted EBITDAR margin before non-controlling interest as a percentage of net revenue was 12.7% during Q2 of 2024, compared to 12.0% in Q2 of 2023. As Marty discussed, Adjusted EBITDAR margins benefited by improved surgical mix, the impact of our cost reduction efforts, as well as the overall improvement in our payer mix. The comparison of Adjusted EBITDA to the prior year is also impacted by approximately $8 million in benefit from government stimulus funds recognized in the second quarter of last year. Specifically, relating to our expenses for the second quarter of 2024, I'd highlight that our contract labor expense declined by approximately $7 million year-over-year, or 22%, as we continue to see a normalization of contract labor utilization and rates across each of our markets and continued improvements in our nursing retention. As a percentage of total salaries and benefits, our contract labor expense for Q2 of 2024 was 4.3%, compared to 5.7% for Q2 of last year. In total, for the second quarter of 2024, salaries and benefits were $624 million, or 42.4% of total revenue, compared to $598 million, or 43.7% of total revenue in the second quarter of last year. Our supplies expense for the quarter was approximately $259 million, or 17.6% of total revenue, compared to $253 million, or 18.5% of total revenue in the second quarter of last year. This ninety basis point decrease in supplies expense as a percentage of revenue reflects improvements in our supply chain performance.... from a number of supply expense initiatives that our team has been implementing this year. Professional fees for the second quarter of 2024 were $272 million, or 18.5% of total revenue, compared to $235 million, or 17.1% of total revenue, in the prior year period. A majority of the increase in professional fees relates to higher hospital-based physician subsidies compared to 2023. So far in 2024, we continue to see some pressure in certain specialties, such as anesthesia and radiology, but overall, we believe that the subsidy dynamic has largely normalized relative to the significant increases we saw throughout 2023. Other operating expenses for Q2 were $115 million, or 7.9% of total revenue, compared to $109 million, or 7.8% of total revenue, in Q2 of last year. The decrease in other operating expenses primarily reflects an approximately $7 million benefit from a sale of aged patient accounts receivable in Q2 of this year. Moving now to cash flow and liquidity. We ended the second quarter with total cash of $335 million. Cash provided by operating activities during the second quarter was $120 million, compared to $43 million during the second quarter of 2023. The increase in cash from operating activities compared to the prior year reflects our improved profitability and higher cash flow, resulting from changes in net working capital. Capital expenditures during the second quarter were $39 million, compared to $34 million in the second quarter of last year. The increase in CapEx was primarily driven by an $8 million increase in growth CapEx, relating to medical imaging equipment and surgical robots. At the end of the second quarter, our total net debt outstanding was $758 million. During the quarter, we repaid $100 million of outstanding borrowings under our Term Loan B using cash on hand, while simultaneously increasing capacity under our undrawn revolving credit facility by $100 million. At the end of the second quarter, our total available liquidity was $624 million. When factoring in the $209 million of net proceeds from the initial public offering in July, our net debt would have been $549 million, and total available liquidity would have been $832 million at the end of the second quarter on a pro forma basis. As of June 30, 2024, our total net leverage, as calculated under our credit agreements, was 2.3 times, and our lease-adjusted net leverage was 4.0 times. Pro forma for the net proceeds of the IPO, our lease-adjusted net leverage was 3.6 times. I'd like to turn now to recap our full-year 2024 financial guidance, which we announced in our press release yesterday afternoon. Total revenue of between $5.75 billion and $5.9 billion. Adjusted EBITDA of between $415 million and $435 million. Net income attributable to Ardent Health Partners of between $163 million and $182 million, implying full-year EPS of between $1.23 and $1.37. Finally, capital expenditures of between $170 million and $185 million. Our guidance for the year reflects total adjusted admissions growth of between 4.0% and 4.5% compared to 2023, and net patient revenue per adjusted admission growth of between 3.0% and 4.0%. Our guidance also reflects an Adjusted EBITDA impact of approximately $27 million from the Oklahoma DPP program. As it relates specifically to our expectations for the second half of the year compared to 2023, we expect to see continued volume and rate growth across our markets, supported by our focus on sustainable operational excellence and margin improvement. Before opening the call up for questions, I also want to provide a quick update on the New Mexico Directed Payment Program. This supplemental program has been approved by the state and signed into law by the Governor of New Mexico. As of August fifth of this year, the program has been submitted to CMS for its approval, which historically takes on average 120-140 days. We'll continue to keep you posted on any material updates to the status of this program going forward. Now, with that, operator, I'd like to open up the line for questions. Thank you. The floor is now open for questions. If you have dialed in and would like to ask a question, please press star one on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. If you are called upon to ask a question and are listening via loudspeaker on your device, please pick up your handset to ensure that your phone is not on mute when asking a question. For this session, we request that you please restrict yourself to one question and one follow-up, and you can reenter the queue for any further follow-up questions. Your first question comes from the line of Jason Cassorla of Citi. Your line is open. ... Great. Thanks, guys, and congrats on the quarter. I just wanted to ask about 2024 EBITDA guidance and what it implies for the back half of the year. You know, if we add back that $63 million of cybersecurity headwind in the fourth quarter of 2023, it seems like 2024 guidance implies that second half EBITDA would basically be flat at the midpoint year-over-year. You know, that comes after meaningful growth year-to-date and the Oklahoma DPP benefit. I guess you have the range out there, but just any color in terms of how you're approaching EBITDA guidance and maybe what the puts and takes are, and that we should be thinking about for the second half. Sure. I appreciate the question. Yeah, you're correct. You know, if you look at just the midpoint of guidance, you know, it would apply pretty, you know, pretty modest, year-over-year growth, relatively flat if you adjust out for cyber. You know, obviously, you know, we're just out of the gate in terms of guidance. You know, we clearly had some benefit in Q2 from a couple things from a timing perspective. We had a sale of aged AR that was a, you know, relatively small amount, but usually we expect those types of events to happen in the back half of the year. So there's just a little bit of timing going on, as well as some supplemental activity. You know, we're early in our obviously, in our public co history and, you know, our expectations are to have guidance that we fully meet. So we, we haven't done anything in terms of modifying guidance at this point. And again, I would point to, you know, real timing activity, as well as if you look at last year, the Oklahoma DPP program was scheduled to go live originally in October of 2023. They postponed the go live until April of this year, but as a consequence, they provided—Oklahoma provided a refund of the SHOPP tax that, and that hit in Q4 of last year, so that was kind of a one-timer in the back half of the year. Okay, great. Thank you. And then maybe just as a follow-up, we're just hoping to give a little bit more color around your ambulatory expansion. I know, I think you guys have previously suggested a $20 million-$25 million kind of annualized spend there. I guess, can you just give us a sense on the pipeline, timing around that ambulatory expansion, what that looks like, and maybe just how you're, you know, perhaps how you're balancing any opportunity to pull that forward or accelerate that spend would be great. Thanks. Yeah, as we said, we implemented or through our urgent care platform by eight facilities the first half of this year. You know, we expect to see meaningful growth in the second half on urgent care as well. We've got the number of de novos and acquisition, targeted acquisitions in the pipeline, but nothing definitive to say. But I would expect to see growth in the second half of this year based upon what's in our pipeline. Your next question comes from the line of Scott Fidel of Stephens. Your line is open. Hi, thanks. Good morning. For the first question, just appreciate the update on the redeterminations and the comment around 20% shifting over to commercial. Just interested if you could share with us what your exchange admissions contributions were in the second quarter to admissions growth and what you're budgeting for the full-year for that as well. Yeah, exchange volumes overall were, you know, up fairly significantly, you know, basically from an admissions perspective, about a third year-over-year. However, you know, for us, it's still a relatively small contribution from a revenue perspective, just over 3% of our revenues. So, you know, the volumes are still relatively modest overall, even though on a year-over-year basis, you know, it is growing, and clearly a big part of that growth has been the redeterminations. Okay, got it. And then as a follow-up question, I thought it might just be helpful if you could walk us through, look in a little more detail. I've actually got a couple questions on this already, just around sort of the sequencing of the Oklahoma DPP and and sort of how that builds into the full-year expectations. As you highlighted in the release, you had around $13 million in the second quarter. You're assuming $27 million for the full-year. So that would sort of imply one more sort of similar payment. But maybe if you could walk us through, is this something that you would expect quarterly or biannually, or is there some conservatism just around that sort of processing of Oklahoma DPP revenues over the course of the year, would be helpful. Yeah, good question, Scott, and I think, you know, that partially was a component of the answer to Jason's question as well, and I know it is a little bit, I'll say confusing. We're expecting, you know, the program is live, went live on April 1, and we'll expect relatively consistent revenue impact from that. You know, we said $13 million in Q2. We would expect relatively consistent revenues, you know, in the coming quarters. There is, of course, a tax component to that, so the net is smaller than that, you know, call that $10 million-$11 million. From a year-over-year perspective, we did have this SHOPP tax refund in Q4 of last year, and that's, that's why the full-year impact, it's not as simple as taking, you know, three times the $13 million, for the rest of the year. However, you know, going into next year, we'll also, from a Q1 perspective, we'll get a full quarter impact of the program, in Q1 of next year, on a year-over-year basis. So, again, that's why it's not as simple, just that SHOPP tax, I'll call it refund last year, makes it not as simple as taking three times the Q2 impact. Hope that makes sense. ... Yeah, it does. Okay, that, that helps, explain that. Okay, great. Thank you. Good thing. Your next question comes from the line of Whit Mayo of Leerink Partners. Your line is open. Hey, thanks. Good morning, guys. Can you maybe spend just a minute on the service line optimization? i think you kind of framed some of the impacts that you saw on surgical trends, calling out dental, ENT, ophthalmology. Just how much did that contribute to the decline? How much do you think that weighs on the metrics for the year? Do you annualize this next year? Is this an ongoing initiative? Just maybe any color would be helpful. Yeah, I think I'll start and then let Marty jump in. You know, from our perspective, when we look at the surgical decline, it essentially, you know, and there's always puts and takes, right? But it essentially covers all of it. And we've also seen pressure, and I think that is a broad industry dynamic as well on our bariatric cases, unrelated to our service line optimization. but i think if we look just at how much of the year-over-year decline on that service line optimization impact, it was effectively the entire amount of the decrease. It was, yeah, actually, slightly more than that. It was, you know, we saw surgical growth when you net in the additions. So we were focusing on taking out some lower level cases, dental, ophthalmology, ENT. You know, if you look at just those three categories, that equates to about 117% of the decline. So we backfilled that with higher acuity cases. We also have been focused on our oncology programs. We closed an OB program last year, in one of our Texas markets, and so all of those things are continuing to play out, and we'll see the rest of that impact, basically cycle out as we go through the balance of this year. Okay. Maybe just, Alfred, I think contract labor, you framed around a 4.3% as a percentage of total SWB this quarter, down from 5.7%, if I get the numbers right. What are you budgeting for in terms of the rest of the year? Do you think you make additional improvement from current levels, or is this a steady state that you would expect? I would say it's closer to steady state. You You know, I wouldn't expect the same kind of quarter-over-quarter decreases that we've seen as we go forward. We're still very focused, you know. Average hourly rate has come down nicely, and we are still very focused on utilization. And of course, you know, from a quarter-over-quarter, we would expect seasonally Q4 to be, you know, our strongest from a volume perspective, and so there will be, you know, more utilization potentially. So, I think we're to, you know, we'll call it the new normal, with still, you know, focus on getting back to pre-pandemic levels. But, we're getting much closer to that, so I don't think we'll see the kind of step functions down that we've seen, you know, last several quarters. Yeah. That being said, we are seeing strong recruitment and retention for our team members, and as that trend continues, we do expect, you know, as Alfred said, to get back towards pre-pandemic levels around those rates, but again, not the significant step down that we saw. Okay, maybe just to clarify that point, just the—I mean, if I take the second quarter, the 4.3% of SWB, that's—that's you're kind of run rating that in, in terms of, like, your guidance for the rest of the year. You're not assuming a material or modest level of improvement? Not assuming a modest, I mean, not assuming a material level of improvement from where we are. Okay, perfect. Thank you. Your next question comes from the line of, Craig Hettenbach of Morgan Stanley. Your line is open. Great. Thanks for the color and the timing of New Mexico. On supplemental payments more broadly, can you just talk about your confidence in expanding and that, and really a contribution to margins as we go forward? Yeah, I think at a macro level, you know, we view these programs as, you know, pretty consistent and enduring. You know, I think now with New Mexico and Tennessee, with their DPP program, something like 44 states have a program in place. So, you know, we think, you know, relatively predictable. Now, obviously, New Mexico has not been approved by CMS yet, and, you know, we'll be back, obviously once that approval has happened. But, yeah, I think from, you know, we think it is, the amounts historically have been largely, quite predictable. Got it. And then just a follow-up question on the strong Adjusted Admissions growth. Can you share any insights or color by some of the markets, like maybe some markets that are trending above? Yeah, it's been pretty consistent throughout our markets. Obviously, the Two- Midnight Rule has been a tailwind in this, and that's been consistent across all of our markets. So, you know, I don't think there's anything at a individual market level that I would particularly point to. Okay, thanks for that. Your next question comes from a line of Kevin Fischbeck of Bank of America. Your line is open. Hi, good morning. This is Joanna Gajuk filling in for Kevin today. Thanks for taking the question. So if I may just follow up on the discussion around the supplemental payment program. So I understand we're waiting for the New Mexico, and you're saying, you know, it's broadly, I guess, accepted program across 44 different states. But I guess as we're thinking, you know, going into elections and what might happen, like, the different scenarios in terms of the outcome and how this could impact the Medicare Supplemental Payment program in particular, right? If Republicans were to take over and try to kind of go after Medicaid, well, we're speaking and then, you know, what—I guess, how much is at risk in your states when it comes to the Supplemental Payment program? Thank you. Yeah, I mean, it's a, it's a good question, and everybody's got that same question on their minds. You know, the, the way in which we've looked at it, as Alfred said, with the approval of New Mexico, the 44 states that have these live. If you go back to the inception of these programs, they started back in 2016 under the Trump administration and then have continued to grow under the Biden administration. And so, given that this is now widespread across the country, you know, we feel that there's, you know, significant durability. CMS has also published guidance, you know, that has to be achieved by 2028 in terms of how these-- how they're gonna try to standardize and normalize these programs across the country. So, you know, I think that also gives us some visibility in terms of how the government is thinking about these programs as a, you know, contributing funding source for these lower-income patients. And so, you know, we have, you know, good reason to believe that, regardless of the election outcomes, that these should have durability. Right. And what do you think about the concept of, you know, some of these states, when they, expanded these supplemental payment programs, they, went with the rate increase all the way up to commercial rates, and some states are, you know, raised the rates, but more kinda in line with Medicare. So would you say that, you know, those states that, went with, you know, higher rates all the way to commercial would be more at risk when it comes to potential, you know, program changes? I think it's just too early to know, you know, what the platforms need. Neither of the candidates have really established any firm guidance on this, and so I think anything that we would say is just complete speculation on that part. Thank you. If I might ask a question on a separate topic. So you talk about your, I guess, you know, managing your balance sheet, but also looking at potential acquisitions. You talk about you actively evaluating a pipeline. So can you talk about your plans? Should we expect, you know, a transaction within the next 12 months? You know, and I guess how many different assets are you looking at? You know, what types of assets are you looking at, when it comes to, you know, targeting expansions? Thank you. Yeah. I mean, we've got a robust pipeline of activity, as everybody knows, that there's a sort of Tale of Two Cities going on in the healthcare world. There are systems like ours that are performing well, and still a lot that are struggling, and so we're in conversations with a number of different opportunities that are attractive. We're gonna be very picky in terms of where—which markets we go into that fit our criteria of those mid-size urban markets, good growth profile, and someplace where we can get a, you know, significant foothold in those markets. At this point, we don't have anything definitive to discuss, but we're encouraged by the pipeline that we have and are hopeful to see an opportunity arise, you know, in the not-too-distant future. That being said, it's too early to put anything definitive out there. Your next question comes from the line of Timothy Greaves of Loop Capital Markets. Your line is open. Hi. Hi, if I could, I wanted to go back to total surgeries and in decline. It seems service line optimization and the move away from lower acuity services to higher ones is the reason for it. I just wanted to kinda, like, go into more of how... What is the depth of services that you guys offer in the higher acuity versus lower acuity services? And maybe further in on that, how much of the split-- what is the split between the lower versus higher surgeries do you guys give? We're full-service providers, absent you know, high-end transplants. You know, we do a full complement of mix of surgeries, orthopedics, neurosurgery, general surgeries, et cetera. And so, you know, the surgeries that we've taken out, as you said, tend to be, you know, higher volumes, but not as a percent of the total. But they're just quicker turnaround cases, and so you see a bigger numeric impact than you would for some of the higher acuity cases that take more time. And so, you know, as we said, the delta that we saw in terms of the surgery decline was fully captured in terms of taking some of those lower margin services out. Not all, but you know, making progress around those, and then backfilling with some of those higher margins. So, Alfred, anything you want to add? No, I think, you know, it's difficult to give a precise answer, you know, or a precise definition of lower acuity and higher acuity, right? Because even within categories of something like orthopedics, there are, you know, I'll say, lower acuity orthopedics and higher acuity orthopedics. You know, to Marty's point, the lower acuity clearly, clearly are a higher volume, and, you know, for having the OR time freed up for a higher acuity surgeries and really focusing on growing, those types of surgeries, you know, spine, orthopedics, has been a, a significant focus. Okay, thank you for taking the question. This concludes our Q&A session. I will now turn the conference back over to Marty for closing remarks. Thank you, everyone, for your support of Ardent as we enter into this exciting new chapter for the company. We believe we've got a strong foundation for profitable growth, and we look forward to keeping you apprised of our progress. With that, that concludes our call today. Thank you. This concludes today's conference call. You may now disconnect.